Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Céleste Lebbé"'
Autor:
Gaëlle Farge, Laurent Mortier, Stéphane Dalle, Olivier Dereure, Sheenu Chandwani, Caroline Dutriaux, Sophie Dalac, Laurie Levy-Bachelot, Laetitia Verdoni, Emilie Scherrer, Clara Allayous, Céleste Lebbé, Emilie Casarotto, B. Oriano
Publikováno v:
Immunotherapy
Immunotherapy, 2021, 13 (11), pp.905-916. ⟨10.2217/imt-2021-0077⟩
Immunotherapy, 2021, 13 (11), pp.905-916. ⟨10.2217/imt-2021-0077⟩
International audience; Aim: To describe real-world pembrolizumab administration and outcomes for advanced melanoma in France. Materials & methods: Using the MelBase longitudinal database, this multicenter historical-prospective study examined treatm
Autor:
Carlos Gomez-Roca, Sylvie Rottey, Thierry Lesimple, Céleste Lebbé, Ahmad Awada, Celine Pages, Antoine Italiano, Philippe Aftimos, Richard F. Kefford, Armin Schueler, Jean Pierre Delord, Vibeke Kruse, Samantha Goodstal, Nadine Houede, Monica Dinulescu, Suzanne Leijen, Jan H.M. Schellens, Sandrine Faivre, Giorgio Massimini, Eric Raymond
Publikováno v:
Targeted Oncology. 16:47-57
Pimasertib is a selective, potent mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor. The aim of this study was to describe the efficacy, safety, and pharmacodynamics of pimasertib at pharmacologically active doses in a cohort of patients wi
Autor:
Ahmad Awada, Monica Dinulescu, Armin Scheuler, Suzanne Leijen, Jan H.M. Schellens, Nadine Houede, Jean Pierre Delord, Carlos Gomez-Roca, Richard F. Kefford, Giorgio Massimini, Vibeke Kruse, Philippe Aftimos, Thierry Lesimple, Antoine Italiano, Celine Pages, E. Raymond, Sandrine Faivre, Sylvie Rottey, Céleste Lebbé
Publikováno v:
Targeted Oncology. 16:37-46
The Ras/Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (Ras/Raf/MEK/ERK) signaling cascade is frequently constitutively activated in human cancers. Pimasertib is a selective and potent adenosine triphosphate non-com
Autor:
Céleste Lebbé, Jeffrey Russell, Caroline Robert, Gülseren Güzel, Thilo Gambichler, Jérémy Lambert, Nicola Fazio, Bartosz Chmielowski, Alexia Marrel, Jean-Jacques Grob, Melissa A. Burgess, Murtuza Bharmal, Sandra P. D’Angelo
Publikováno v:
The Patient
Background and Objective Avelumab is approved for the treatment of metastatic Merkel cell carcinoma, a rare aggressive skin cancer with a poor prognosis. The aim of this qualitative study embedded in a clinical trial was to explore patient experience
Autor:
Fareeda Hosein, Veerle de Pril, Jon M. Richards, Jean-Jacques Grob, Vanna Chiarion-Sileni, Henrik Schmidt, Virginia Ferraresi, Alessandro Testori, Omid Hamid, Jeffrey S. Weber, Jedd D. Wolchok, Alexander M.M. Eggermont, Paolo A. Ascierto, Stefan Suciu, Caroline Robert, Michael Smylie, Reinhard Dummer, Michal Kicinski, Céleste Lebbé, Michele Maio
Publikováno v:
Eggermont, A M M, Chiarion-Sileni, V, Grob, J J, Dummer, R, Wolchok, J D, Schmidt, H, Hamid, O, Robert, C, Ascierto, P A, Richards, J M, Lebbe, C, Ferraresi, V, Smylie, M, Weber, J S, Maio, M, Hosein, F, de Pril, V, Kicinski, M, Suciu, S & Testori, A 2019, ' Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma : long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial ', European Journal of Cancer, vol. 119, pp. 1-10 . https://doi.org/10.1016/j.ejca.2019.07.001
Background: Since 2015, adjuvant therapy with ipilimumab is an approved treatment for stage III melanoma based on a significantly prolonged recurrence-free survival (RFS). At a median follow-up of 5.3 years, RFS, distant metastasis-free survival (DMF
Autor:
Christoph Hoeller, Marie-Francoise Avril, Pietro Quaglino, François Aubin, Lars Bastholt, Takashi Inozume, Virginia Ferraresi, Michael B. Jameson, Kevin B. Kim, Oliver Bechter, Dirk Schadendorf, Kenji Yokota, Carmen Loquai, Maria-Jose Passos, Inge Marie Svane, Michele Maio, Catherine Barrow, Frank Meiss, Nageatte Ibrahim, Andrzej Mackiewicz, Phillip Parente, Tatsuya Takenouchi, Caroline Dutriaux, Piotr Rutkowski, Alfonsus J M van den Eertwegh, Paola Queirolo, Catriona M. McNeil, Peter Mohr, Felix Kiecker, Susana Puig, Friedegund Meier, Lutz Kretschmer, Alexander C.J. van Akkooi, Alex Menzies, Timothy Crook, Christian U. Blank, Suzana Matkovic, Michael C. Brown, Ragini R. Kudchadkar, Max Levin, Rüdiger Hein, Tanja Skytta, Gerald P. Linette, Clemens Krepler, Adnan Khattak, Ernest Marshall, Joseph Kerger, Oddbjorn Straume, Laurent Mortier, Jochen Utikal, Micaela Hernberg, James Larkin, Yoshio Kiyohara, Mario Mandalà, Henrik Schmidt, Daniil Stroyakovskiy, Pablo Luis Ortiz Romero, Naoya Yamazaki, John Walker, Anna Maria Di Giacomo, Lionel Geoffrois, Jean-Philippe Lacour, Caroline Robert, Vincent Descamps, Shahneen Sandhu, Gil Bar-Sela, Paul C. Nathan, Marcin Dzienis, Ralf Gutzmer, Claus Garbe, Andrey Meshcheryakov, Patrick Combemale, Martin Fehr, Guzel Mukhametshina, Helena Kapiteijn, Geke A. P. Hospers, Jun Aoi, Andrew Haydon, Rutger H. T. Koornstra, Marie-Thérèse Leccia, Sigrun Hallmeyer, Pier Francesco Ferrucci, Jean-Jacques Grob, Leonel Hernandez-Aya, Jan-Christoph Simon, Vanna Chiarion Sileni, Alain Algazi, Lidija Sekulovic, Sandrine Marreaud, Bernard Fitzharris, Jacob Schachter, Xinni Song, Wolf-Henning Boehncke, Rahima Jamal, Paul Lorigan, Maureen J.B. Aarts, Reinhard Dummer, Mike McCrystal, César Martins, Reiner Hofmann-Wellenhof, Alexander M.M. Eggermont, Carola Berking, Elaine Dunwoodie, Bernard Guillot, Michal Kicinski, Philippe Saiag, Céleste Lebbé, Thierry Lesimple, Stefan Suciu, Michal Lotem, Paula Ferreira, Mohammed M. Milhem, Laurent Machet, Patrick Terheyden, Anna Katharina Winge-Main, Peter Hersey, Jean-Francois Baurain, Axel Hauschild, Stéphane Dalle, Jean-Philippe Arnault, Paolo A. Ascierto, Gerard Groenewegen, Florent Grange, Georgina V. Long, Victoria Atkinson, Philippa Corrie, Matteo S. Carlino, Thomas Jouary, Daniel Hendler, Richard Casasola, Ashita Waterston, Jessica C. Hassel
Publikováno v:
EORTC Melanoma Group 2021, ' Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial ', The Lancet Oncology, vol. 22, no. 5, pp. 643-654 . https://doi.org/10.1016/S1470-2045(21)00065-6
Lancet Oncology, 22, 643-654
Lancet Oncology, 22, 5, pp. 643-654
Lancet Oncology
Lancet Oncology, 2021, 22 (5), pp.643-654. ⟨10.1016/S1470-2045(21)00065-6⟩
The Lancet Oncology, 22(5), 643-654. Lancet Publishing Group
Lancet Oncology, 22, 643-654
Lancet Oncology, 22, 5, pp. 643-654
Lancet Oncology
Lancet Oncology, 2021, 22 (5), pp.643-654. ⟨10.1016/S1470-2045(21)00065-6⟩
The Lancet Oncology, 22(5), 643-654. Lancet Publishing Group
Background: The European Organisation for Research and Treatment of Cancer (EORTC) 1325/KEYNOTE-054 trial assessed pembrolizumab versus placebo in patients with resected high-risk stage III melanoma. At 15-month median follow-up, pembrolizumab improv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca46af8de45fdf5ffd9d70f717e94208
https://research.vumc.nl/en/publications/8aae177c-dfa8-4325-b8c2-e7b1d7339027
https://research.vumc.nl/en/publications/8aae177c-dfa8-4325-b8c2-e7b1d7339027
Autor:
Céleste Lebbé, Andrew S. Brohl, Meliessa H. Hennessy, Michele Milella, Patrick Terheyden, Kent C. Shih, Paul Nghiem, Isaac Brownell, Gerald P. Linette, Karl D. Lewis, Shailender Bhatia, Murtuza Bharmal, Omid Hamid, Michael Schlichting, Sandra P. D'Angelo, Janice M. Mehnert, Matthias Hunger
Publikováno v:
Cancer Immunology, Immunotherapy
Background Response rates are primary endpoints in many oncology trials; however, correlation with overall survival (OS) is not uniform across cancer types, treatments, or lines of therapy. This study explored the association between objective respon
Autor:
Philip Friedlander, Claudia Pföhler, Michael Max Sachse, Max Schlaak, Carola Berking, Lavinia Spain, Alexander M. Menzies, Friedegund Meier, Rafaela Kramer, Kinan Hayani, Céleste Lebbé, Katharina C. Kähler, Lisa Zimmer, Milena Dudda, Anne Zaremba, Alvaro Moreira, Jessica C. Hassel, Georgina V. Long, Barouyr Baroudjian, Lydia Reinhardt, Alison Weppler, Adriana Hepner, Matteo S. Carlino, Carmen Loquai, Paul J Bröckelmann, Anja Gesierich, Tomohiro Enokida, Douglas B. Johnson, Lucie Heinzerling, Thomas Eigentler, Makoto Tahara, Martin Salzmann, Selma Ugurel
Introduction With the increasing use of checkpoint inhibitors, rare immune-related adverse events (irAE) are being identified. Haematological irAE (hem-irAE) are difficult to treat and have shown high mortality rates. In order to improve side-effect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fbea5c242e2582a869d1911e0b68e0cd
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85102118984
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85102118984
Autor:
Céleste Lebbé, Katharina C. Kähler, Egle Ramelyte, Elisabeth Livingstone, Lucie Heinzerling, Axel Hauschild, Phil F. Cheng, Frédéric Toussaint, Camille L. Gerard, Paolo A. Ascierto, Joanna Mangana, Clara Allayous, Sarah Schäfer, Reinhard Dummer, Anne Zaremba, Jessica C. Hassel, Florentia Dimitriou, Lucia Festino, Olivier Michielin
Publikováno v:
European journal of cancer (Oxford, England : 1990). 149
Background Anti-PD1–based immunotherapy is currently used in most patients with advanced melanoma. Despite the remarkable data regarding overall survival, the optimal treatment duration is still unknown. Methods We evaluated the outcome of 125 pati
Autor:
Céleste Lebbé, Sarah Leonard-Louis, Valérie Gounant, Yannick Le Corre, Barouyr Baroudjian, Monica Dinulescu, Vincent Descamps, Baptiste Hervier, Alain Dupuy, Julie Delyon, Bertille Bonniaud, Nausicaa Malissen, Amandine Weill, P. Celerier, Florence Brunet-Possenti, Valentine Heidelberger, Charlée Nardin, Ludovic Doucet, Solenne Brosseau, Géraldine Jeudy, E. Maubec, Adèle de Masson, Dimitri Psimaras, Gérard Zalcman, Groupe de cancérologie cutanée, Christine Longvert, François Aubin, Laurent Machet, Lydia Deschamps
Publikováno v:
Rheumatology (Oxford, England). 60(12)
Objectives The occurrence of immune-related myositis (irM) is increasing, yet there are no therapeutic guidelines. We sought to analyse the current therapeutic strategies of irM and evaluate the outcomes of immune checkpoint inhibitors (ICIs) rechall